Smad4 is predictive for response in neoadjuvant treated esophageal squamous cell carcinoma

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4591-4591
Author(s):  
B. L. Brücher ◽  
F. Pühringer-Oppermann ◽  
M. Sarbia
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Predictive Value ◽  
Roc Analysis ◽  
Locally Advanced ◽  
Rna Extraction ◽  
Histopathological Response ◽  
Tgf Β1

4591 Background: The evaluation of the prevalence of TGF-β1-pathway gene expressions (TGF-β1, Smad7 and Smad4) and its predictive value for histopathological response in patients with esophageal squamous cell carcinoma and neoadjuvant radiochemotherapy. Methods: RNA was prepared from pretherapeutic taken formalin-fixed and paraffin-embedded biopsies of 98 patients with histological proven locally advanced ESCC (cT3, cN0/+, cM0), who underwent preoperative combined simultaneous RTx/CTx with consecutive esophagectomy. All tumor biopsies underwent tumor-cell-microdissection, RNA-extraction and real-time TaqMan reverse transcriptase- polymerase chain reaction. RT-PCR-measurements were made by doublet measuring. Quantitative mRNA expression of TGFβ1 and its downstream effectors Smad4 and Smad7 was correlated with histopathological response by the percentage of residual tumor cells. Analysis was performed by dichotomized calculation and for determination of a cut-off by ROC-analysis. Results: Dichotomized analysis revealed the following median values: Smad4=0.098± 0.7 (CI: 0.024–0.396), Smad7=1.9250±1.7 (CI: 0.4–16.1) and TGFβ1=6.427±4.86 (CI: 0- 25.7). Cross-tabs-analysis for histopathological response disclosed the following correlations: TGFβ1 (p=0.671), Smad7 (p=0.672) and Smad4 (p=0.038). ROC-analysis revealed a Smad4-cut-off of 0.0635 by an area-under-curve of 6280 (p=0.038). Consecutive re-cross-tabs-analysis of histopathological response revealed a sensitivity of 80% (p=0.013). The pretherapeutic predictive value of Smad4 was 73%. Medians in survival was not reached during follow-up, whether TGFβ1 (p=0.519), Smad7 (p=0.5728) nor Smad4 (p=0.552). Histopathological responders showed a significant better survival compared to nonresponders (p<0.0001). Conclusions: High levels of Smad4 gene expression are significantly correlated with histopathological response. ROC-Analysis identified a cut-off of Smad4 with a sensitivity of 80% and a predictive value of 73%. No significant financial relationships to disclose.

scholarly journals Concurrent chemoradiotherapy with S-1 compared with concurrent chemoradiotherapy with docetaxel and cisplatin for locally advanced esophageal squamous cell carcinoma

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Xi-Lei Zhou ◽  
Chang-Hua Yu ◽  
Wan-Wei Wang ◽  
Fu-Zhi Ji ◽  
Yao-Zu Xiong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Adverse Events ◽  
Esophageal Squamous Cell Carcinoma ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Concurrent Chemoradiotherapy ◽  
Response Rate ◽  
Locally Advanced ◽  
Grade 3

Abstract Background This retrospective study was to assess and compare the toxicity and efficacy of concurrent chemoradiotherapy (CCRT) with S-1 or docetaxel and cisplatin in patients with locally advanced esophageal squamous cell carcinoma (ESCC). Methods Patients with locally advanced ESCC who received CCRT with S-1 (70 mg/m2 twice daily on days 1–14, every 3 weeks for 2 cycles, S-1 group) or docetaxel (25 mg/m2) and cisplatin (25 mg/m2) on day 1 weekly (DP group) between 2014 and 2016 were retrospectively analyzed. Radiotherapy was delivered in 1.8–2.0 Gy per fraction to a total dose of 50–60 Gy. Treatment-related toxicities (Common Terminology Criteria for Adverse Events version 4.0), response rate, and survival outcomes were compared between groups. Results A total of 175 patients were included in this study (72 in the S-1 group and 103 in the DP group). Baseline characteristics were well balanced between the two groups. The incidence of grade 3–4 adverse events were significantly lower in the S-1 group than that of the DP group (22.2% vs. 45.6%, p = 0.002). In the DP group, elderly patients (> 60 years) had a significantly higher rate of grade 3–4 adverse events than younger patients (58.1% vs. 31.3%, p = 0.01). The objective overall response rate (complete response + partial response) was 68.1% in the S-1 group, and 73.8% the DP group (p = 0.497). The 3-year overall survival was 34.7% in the S-1 group, and 38.8% in the DP group (p = 0.422). The 3-year progression free survival in the DP group was higher than that in the S-1 group but without significant difference (33.0% vs. 25.0%, p = 0.275). Conclusion CCRT with S-1 is not inferior to CCRT with docetaxel and cisplatin and is better tolerated in in elderly patients with locally advanced ESCC.

scholarly journals Endoscopic traversability in patients with locally advanced esophageal squamous cell carcinoma

Medicine ◽  
2017 ◽  
Vol 96 (51) ◽  
pp. e9441 ◽  
Author(s):  
Hae Jin Shin ◽  
Hee Seok Moon ◽  
Sun Hyung Kang ◽  
Jae Kyu Sung ◽  
Hyun Yong Jeong ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Esophageal Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Locally Advanced

scholarly journals Quantitative dynamic contrast-enhanced MR imaging can be used to predict the pathologic stages of oral tongue squamous cell carcinoma

2020 ◽  
Author(s):  
Na Guo ◽  
Weike Zeng ◽  
Hong Deng ◽  
Huijun Hu ◽  
Ziliang Cheng ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Predictive Value ◽  
Roc Analysis ◽  
Pharmacokinetic Parameters ◽  
Oral Tongue ◽  
Dce Mri ◽  
Dynamic Contrast Enhanced ◽  
Contrast Enhanced

Abstract Background: To investigate whether quantitative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) pharmacokinetic parameters can be used to predict the pathologic stages of oral tongue squamous cell carcinoma (OTSCC). Methods: For this prospective study, DCE-MRI was performed in participants with OTSCC from May 2016 to June 2017. The pharmacokinetic parameters, including K trans , K ep , V e , and V p , were derived from DCE-MRI by utilizing a two-compartment extended Tofts model and a three-dimensional volume of interest. The postoperative pathologic stage was determined in each patient based on the 8th AJCC cancer staging manual. The quantitative DCE-MRI parameters were compared between stage I-II and stage III-IV lesions. Logistic regression analysis was used to determine independent predictors of tumor stages, followed by receiver operating characteristic (ROC) analysis to evaluate the predictive performance. Results: The mean K trans , K ep and V p values were significantly lower in stage III-IV lesions compared with stage I-II lesions ( p = 0.013, 0.005 and 0.011, respectively). K ep was an independent predictor for the advanced stages as determined by univariate and multivariate logistic analysis. ROC analysis showed that K ep had the highest predictive capability, with a sensitivity of 64.3%, a specificity of 82.6%, a positive predictive value of 81.8%, a negative predictive value of 65.5%, and an accuracy of 72.5%. Conclusion: The quantitative DCE-MRI parameter K ep can be used as a biomarker for predicting pathologic stages of OTSCC.

Sign in / Sign up

Export Citation Format

Share Document